Biomarker der kardiorenalen Achse
Biomarkers of the Cardiorenal Axis

18.-19. January 2018

Multiplex-Proteomics
January 17, 2018
Sehr geehrte Frau Kollegin,
sehr geehrter Herr Kollege,


Wir hoffen, mit diesem Programm Ihr Interesse zu wecken und würden uns über viele Teilnehmer und gute Diskussionen freuen.

Prof. Dr. med. Christoph Wanner
Prof. Dr. med. Winfried März
Prof. Dr. med. Bernhard K. Krämer

Die Veranstaltung wurde bei der Landesärztekammer Bayern zur Zertifizierung angemeldet.

Dear Colleagues,

The pathophysiological links between diseases of the heart and the kidney stay in the focus of scientific interest. Our understanding of this interactions will be based on the consistent application of systems biology approaches. The cooperation between the German Diabetes Dialysis (4D) - Study and the Ludwigshafen Risk and Cardiovascular Health (LURIC) Study reflects these developments. Still more than 20 years after initiation of both studies, many scientific interactions have evolved between the contributing scientists.

Also in 2018, the meeting „Biomarkers of Cardiorenal Axis“ is intended to display the state of the biomarker research at the interfaces between Cardiology, Nephrology and Laboratory Medicine and related disciplines.

For the first time in 2018 and in cooperation with the support of Olink Proteomics, Uppsala, Sweden, we will be offering a satellite symposium on addressing the use of the Proximity Extension Assay (PEA) in biomarker research on Wednesday, January 17, 2018. The number of participants in this event is limited. We therefore ask for early registration.

We hope to draw your interest with this program and would be excited about many many participants and good discussions.

Prof. Dr. med. Christoph Wanner
Prof. Dr. med. Winfried März
Prof. Dr. med. Bernhard K. Krämer

This event was submitted to the Medical Association for CME certification.
Wednesday, January 17, 2018

Getting to the heart of the matter - targeted protein biomarker discovery for the advancement of precision medicine in cardiology and nephrology

11:15  Arrival, registration, coffee
11:45  Lunch
12:30  Opening and overview on the topics of the meeting
      A. Ballagi, Uppsala
      W. März, Mannheim
12:40  Proximity extension assay and applications
      Proximity Extension Assay (PEA) - A technology enabling targeted protein biomarker research
      Olink R&D, Uppsala
12:40  Prognostic biomarkers associated with cardiovascular Events in atrial fibrillation:
      Insights from the Aristotle Trial using Proximity Extension Assay (PEA)-technology
      Agneta Siegbahn, Uppsala
13:00  Plasma proteomics for epidemiology: combining antibody and mass spectrometry-based measurements
      M. Mayr, London
13:20  Biomarkers reflecting tissue injury and repair in prediction of cardiovascular disease
      J. Nilsson, Lund
13:50  Biomarker for cardiovascular precision medicine. Are we there yet?
      F. Zannad, Nancy
14:00  Screening multiple biomarkers for associations with major cardiovascular events
      L. Wallentin, Uppsala
14:10  Epidemiological studies to advance precision medicine
      For further information on the proximity extension technique visit www.olink.com
14:40  Screening multiple biomarkers for associations with major cardiovascular events
      L. Wallentin, Uppsala
15:10  Biomarker discovery in cardiovascular and renal disorders
15:30  Experience from renal cohorts with CVD endpoints and preliminary results from urine analyses
      B. Fellström, Uppsala
15:50  Plenary discussion
16:00  Proteomic analysis; insights from the Aurora trial
      P. Rossinol, Nancy
16:20  Experience from renal cohorts with CVD endpoints and preliminary results from urine analyses
      B. Fellström, Uppsala
17:40  Closing remarks
      A. Ballagi, Uppsala
      W. März, Mannheim
17:50  End of the first day meeting
19:30  Evening event: Wine tasting at the Residenz Würzburg
Thursday, January 18, 2018

9:00   Registration, coffee

9:30   Welcome and introduction into the topic of the meeting
       C. Wanner, Würzburg,
       W. März, Mannheim,
       B.K. Krämer, Mannheim

9:45   Perspectives
       Chair: P. Lansberg, Amsterdam

9:45   Translating clinical trials into patient care
       T. Wierzbicki, London

10:15  EMPA-REG Outcome: Nephroprotection through SLGT2 inhibition
       C. Wanner, Würzburg

10:45  New opportunities and obstacles for biomarker based decision support in cardiovascular care
       L. Wallentin, Uppsala

11:15  Coffee Break

11:30  Genomics
       Chair: Hans Dieplinger, Innsbruck

11:30  Novel drug targets arising from genome-wide association studies
       H. Schunkert, Munich

12:00  TBD
       K. Stefansson, Rejkjavic

12:30  Recent developments in Mendelian randomization studies in the age of large-scale accessible genomics data
       J. Zheng, Bristol

13:00  Lunch Break

13:30  Guided Poster Discussion
       Chair: B. Fellström, Uppsala,
       E. Windler, Hamburg

15:00  Workshop I: Metabolism and Inflammation
       Chair: M. Herrmann, Graz

15:00  LDL cholesterol: really the culprit?
       R. Laaksonen, Tampere

15:25  Lipoproteins and inflammation
       T. Speer, Homburg

15:50  Lipid-lowering by diet: Hard facts, pious wishes?
       S. Lorkowski, Jena

16:15  Afamin is associated with prevalent and incident type 2 diabetes in the general population and predictive for gestational diabetes in pregnancy
       H. Dieplinger

15:00  Workshop II: Biomarkers of kidney disease
       Chair: H.J. Anders, Munich

15:00  Does iron deficiency affect the interaction between FGF-23 and cardiovascular disease?
       G. Heine, Homburg

15:25  The role of vitamin K in vascular calcification
       V. Brandenburg, Aachen

15:50  The Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease Study (MiRENDa) Study
       F. Hammer, Würzburg

16:15  Tubular Dickkopf-3 and the development of renal atrophy and fibrosis
       D. Fliser, Homburg

16:40  Coffee Break
Thursday, January 18, 2018

17:00  **Workshop III: Biomarkers of Heart Disease**  
Chair: J. Scherberich, Munich

17:00  Inflammatory cells in heart disease  
A. Zirlik, Freiburg

17:25  Gut microbiota and vascular disease  
N. Marx, Aachen

17:50  Serum Uromodulin and cardiovascular mortality  
M. Kleber, Mannheim

18:15  Lipoprotein analysis by nuclear magnetic resonance spectroscopy  
P. Pagel, Regensburg

17:00  **Workshop IV: Biomarkers of Kidney Disease**  
Chair: A. Ritsch, Innsbruck

17:00  Novel mechanisms of vascular calcification and clinical implications  
J. Völkl, Berlin

17:25  SuPAR in clinical cohorts  
Claudia Sommerer, Heidelberg

17:50  Parameters of calcium and phosphate metabolism in cardiac surgical patients – Risk markers of clinical outcome  
A. Zittermann, Bad Oeyenhausen

18:15  „Proteasuria – a novel mechanism of edema development in the nephrotic syndrome  
F. Artunc, Tübingen

18:35  End of the second day

20:00  Get together

Friday, January 19, 2017

8:30  **Clinical Trials**  
Chair: B. Fellström, Uppsala

8:30  Translational science: From biology to therapeutics  
U. Fraass, Munich

9:00  PCSK9 – Update  
U. Laufs, Leipzig

9:30  CANTOS: Canakinumab for everyone?  
W. König, München

10:00  **Coffee Break**

10:15  **Renocardial markers**  
Chair: W. Herrmann, Homburg

10:15  Carbamylated albumin – update 2018  
A. Berg, Boston

10:45  Circulating permeability factor suPAR: From concept to clinic  
J. Reiser, Chicago

11:15  Omega 3 index and blood pressure – a causal relationship?  
C. von Schacky, Munich

11:45  Vitamin D: still hot?  
S. Pilz, Graz

12:15  **Wrap up**  
C. Wanner, Würzburg,  
W. März, Mannheim,  
B. K. Krämer, Mannheim

12:30  **Lunch and farewell**
Poster Presentations

Prognostic value of Cathepsin S in the 4D trial
H.J. Anders et al., Munich

Prognostic significance of hemodynamic parameters in hemodialysis patients
F. Artunc et al., Tübingen

Effect of spironolactone on vascular function in patients on hemodialysis
S. Bausch et al., Würzburg

A critical update on solarium use and risk for malignant melanoma: meta-analysis and evidence-based systematic review
B. Burgard et al., Homburg

Testosterone in dialysis patients
J.J. Carrero et al., Würzburg

Effect of the MoKaRi diet on the plasma lipidome
Christine Dawczynski et al., Jena

The association of INR with mortality in patients referred for coronary angiography
Graciela Delgado et al., Mannheim

Clinical benefit of a short term dietary oatmeal intervention in patients with type 2 diabetes mellitus and severe insulin resistance: A cross-over study
Graciela Delagodo et al., Mannheim

The diagnostic value of high sensitivity troponin in dialysis patients
Christane Drechsler et al., Würzburg

Lipoprotein (a) in the DETECT study
A. Dressel et al., Mannheim

Health economic evaluation of PCSK9-Inhibition
A. Dressel et al., Mannheim

Non-oxidised PTH and clinical outcomes in patients with coronary artery disease
T. Dschietzig, Berlin and Bensheim

Neprilysin in CKD
I. Emrich, Homburg

Beta trace protein and mortality
D. Enko et al., Steyr

Prevalence of familial hypercholesterolemia in the DEGS study
F. Fath et al., Mannheim

H-ALERT: An approach to decision support in primary care
F. Fath et al., Mannheim

The aldosterone to renin rato in the clinical laboratory
T. Fenyvesi et al., Weiden

Prevalence an determinants of vitamin D deficieny in Germany
T. Fenyvesi et al., Weiden

ODIN: Mendelian randomization of vitamin D and mortality
M. Gaksch et al., Graz

Effects of vitamin D supplementation on its metabolism in vitamin D insufficient adults
M. Gaksch et al., Graz

Development of a scoring system for predicting the efficacy of statin treatment in patients on hemodialysis
B. Genser et al., Vienna
Poster Presentations

Time on hemodialysis and clinical efficacy of statins in the 4D study
B. Genser et al., Vienna

Systems biology approaches to risk prediction
Ingrid Gergei et al., Mannheim

Genome wide association study of klotho
Ingrid Gergei et al., Mannheim

Galektin 3 – binding protein and CD163 interaction
C. Gleissner et al., Heidelberg

Assessment of the heart age using the Coropredict multimarker panel
Tanja Grammer et al., Mannheim

Left ventricular hypertrophy measured by MRI, echocardiography and ECG in patients on hemodialysis
S. Grebe et al., Würzburg

Galectin 3 – interaction with renin-angiotensin system
M. Grübner et al., Bern

7-DHC and mortality in the LURIC study
M. Grübner et al., Bern

“Auss Dir ein Herz”: the Austrian registry for familial hypercholesterolemia
Gabriele Hanauer-Mader et al., Vienna

Mineralocorticoid hormone antagonism and its metabolic consequences in hemodialysis patients
T. Hauser et al., Würzburg

Cellular cholesterol efflux in participants of the Young Fins Study
Monika Hunjadi et al., Innsbruck

A case of glycerol kinase deficiency with pseudohypertriglyceridemia
Christel König, G. Klose et al., Bremen

Prevalence of familial hypercholesterolemia in the LURIC study estimated by the CARRENAL custom designed microarray
Kleber et al., Mannheim

Saturated fatty acids and mortality
M. Kleber et al., Mannheim

Genome wide association study of homoarginine using the HRC reference panel
M. Kleber et al., Mannheim

Vascular adhesion molecules and severe obesity – a subgroup analysis of the LURIC study
M. Kleber et al., Mannheim

Mortality prediction in stable hemodialysis patients with YKL-40
G. Lorenz et al. Munich

The NutriCARD cluster
S. Lorkowski et al., Jena

Measurement of vitamin D metabolites by mass spectroscopy
S. Zelzer et al., Graz

Thyroid function and vitamin D
A. Merke et al., Bensheim

Vitamin D in the DETECT study
A. Merke et al., Bensheim

Thyroid metabolism and low density lipoproteins
A. Merke et al., Bensheim
Poster Presentations

Regional purchasing power and mortality in the Rhine-Neckar Region
Angela Moissl et al., Mannheim

Homoarginine - a prognostic indicator in adolescents and adults with complex congenital heart disease?
Tanja M. Raedle-Hurst, Homburg

Telomere length and mortality in the LURIC study
Irene Pusceddu et al., Bozen

Variants of genes involved in skin pigmentation are associated with vitamin D concentrations
R. Saternus et al., Homburg

Comparison of contemporary methods to measure lipoprotein (a)
H. Scharnagl et al., Graz

Effects of PCSK9 inhibition on lipoprotein fractions and circulating PCSK9
H. Scharnagl et al., Berlin

Genetics of patients with clinical suspicion of familial hypercholesterinemia of a lipidology specialty outpatients unit
Ulrike Schatz et al., Dresden

Apolipoprotein C3 and mortality in the LURIC study
G. Silbernagel et al., Graz

NMR resolves HDL subfractions with differential effects on mortality
G. Silbernagel et al., Graz

LDL triglycerides, but not LDL cholesterol predict mortality in the LURIC study
G. Silbernagel et al., Graz

Cascade Screening and Registry for High Cholesterol (CaRe-High): interim results
Nina Schmidt, Ulrike Schatz et al., Mannheim

Role of vitamin D deficiency in chronic obstructive pulmonary disease - an overview
R. Siekmeier et al., Bonn

Role of vitamin D deficiency in asthma bronchiale - an overview
R. Siekmeier et al., Bonn

Monitoring of the NFAT regulated gene expression in NTX patients treated with tacrolimus
Claudia Sommerer et al., Heidelberg

Hepcidin and mortality in the LURIC study
P. Strnad et al., Aachen

Characteristics of long-term survivors in 4D
S. Triebsvetter et al, Würzburg

Effects of vitamin D supplementation on FGF23: a randomized-controlled trial
C. Trummer et al., Graz

Phosphate meets uromodulin
J. Scherberich et al., Munich

Effect of Vitamin D supplementation on the RAAS system in end-stage heart failure patients
A. Zittermann et al., Bad Oeynhausen

ADMA und MPO: Is there an interaction?
Sieglinde Zelzer et al., Graz
Poster Presentations

Effects of declining renal function and possible thresholds of renal function on plasma malondialdehyde and myeloperoxidase concentrations from the BIOCLAIMS Study
Sieglinde Zelzer et al., Graz

Link between myeloperoxidase, asymmetric dimethylarginine and the renin-angiotensin-aldosterone-system in cardiovascular risk patients: Cross-sectional findings from the Ludwigshafen Risk and Cardiovascular Health (LURIC) Study Lipoprotein (a) and long-term prognosis in the LURIC study
Sieglinde Zelzer et al., Graz

Lipoprotein (a) and long-term prognosis in the LURIC study
S. Zewinger et al., Homburg Saar
Biomarkers of the cardiorenal axis

MEETING VENUE
Deutsches Zentrum für Herzinsuffizienz
Universitätsklinik Würzburg
Am Schwarzenberg 15, Haus A15
97078 Würzburg

MEETING TIMES
Wednesday, January 17, 2018
12:30 – 17:50

Thursday, January 18, 2018
9:00 – 18:35

Friday, January 19, 2018
8:30 – 12:30

ORGANIZERS
D·A·CH-Gesellschaft Prävention von Herz-Kreislauf-Erkrankungen e. V.
Schulterblatt 120
c/o MasterMedia GmbH
20357 Hamburg

Medizinische Klinik V
Universitätsmedizin Mannheim
Theodor-Kutzer-Ufer 1-3
68167 Mannheim

SYNLAB Akademie für Ärztliche Fortbildung
SYNLAB Holding Deutschland GmbH
P5,7
68161 Mannheim

ADDITIONAL POSTERS AND INFORMATION
Do you wish to contribute a poster?
Do you need other information?

PLEASE CONTACT
Prof. Dr. med. Christoph Wanner
Universitätsklinikum Würzburg
Medizinische Klinik und Poliklinik I
Abteilung Nephrologie
Oberdürrbacher Straße 6
97080 Würzburg
Telefon +49 931 201-39030
Telefax +49 621 201-639030
E-Mail Wanner_C@ukw.de

Prof. Dr. med. Bernhard K. Krämer
Medizinische Klinik V
Universitätsmedizin Mannheim
Theodor-Kutzer-Ufer 1-3
68167 Mannheim
Telefon +49 621 383-5172
Telefax +49 621 383-3804
E-Mail bernhard.kraemer@umm.de

Univ.-Prof. Dr. med. Winfried März
SYNLAB Akademie für Ärztliche Fortbildung
SYNLAB Holding Deutschland GmbH
P5,7
68161 Mannheim
Telefon +49 621 43179-432
Telefax +49 621 43179-433
E-Mail winfried.maerz@synlab.com
Logistics

Biomarkers of the cardiorenal axis

LOCATION

Deutsches Zentrum für Herzinsuffizienz
Universitätsklinik Würzburg
Am Schwarzenberg 15, Haus A15
97078 Würzburg
**Sponsors**

**Biomarkers of the cardiorenal axis**

**MAIN SPONSOR**

AMGEN GmbH
Munich 16,000 Euro

**SPONSORS**

Abbott GmbH & Co. KG
1,000 Euro

Alexion Pharma Germany GmbH
1,000 Euro

Axon Lab AG
1,500 Euro

BASF – The Chemical Company
1,000 Euro

Bayer Vital GmbH
1,500 Euro

bestbion dx GmbH
500 Euro

Boehringer Ingelheim Pharma GmbH & Co. KG
4,000 Euro

DiaSorin Deutschland GmbH
1,000 Euro

Immundiagnostik AG
500 Euro

Lilly Deutschland GmbH
2,000 Euro

MSD Sharp & Dohme GmbH
1,000 Euro

numares AG
1,000 Euro

Ocupharm GmbH
1,000 Euro

Olink Proteomics
10,000 Euro

Sanofi-Aventis Deutschland GmbH
4,000 Euro

Shire Deutschland GmbH
1,000 Euro

Siemens Healthcare Diagnostics GmbH
1,000 Euro
Registration

Biomarkers of the cardiorenal axis

Please issue your binding registration by 22.12.2018 latest to www.synlab.com/de/mensch/fortbildung, by e-mail to manuela.hormuth@synlab.com or winfried.maerz@synlab.com or by fax to +49 (0)621 43179-433.

CONTACT

SYNLAB Akademie für Ärztliche Fortbildung
SYNLAB Holding Deutschland GmbH
P5, 7
68161 Mannheim
Telefon +49 (0) 621 43179-432
Telefax +49 (0) 621 43179-433
E-Mail manuela.hormuth@synlab.com
winfried.maerz@synlab.com

We kindly ask you for binding registration, as non-attendance will generate avoidable costs for the organizers.

TEILNAHME SYMPOSIEN

I will participate with ___ person(s) on the following days

☐ ___ person(s) on 17.01.2018
☐ ___ person(s) on 18.01.2018
☐ ___ persons on 19.01.2018

TEILNAHME ABENDVERANSTALTUNG

☐ Olink – 17.01.2018 only possible upon participation in the Olink satellite meeting
☐ Get together – 18.01.2018

HOTELÜBERNACHTUNG

Number of nights ___

☐ Arrival 16.01.2018
☐ Arrival 17.01.2018
☐ Arrival 18.01.2018

Please provide information completely and clearly

__________________________________________________
Address

__________________________________________________
Telephone and fax

__________________________________________________
E-mail

__________________________________________________
Participant name(s)

Date, signature, and stamp
Good News: You’re automating your lab.
Best News: We perform over 900 workflow consultations each year.

Siemens Healthineers consultants ensure that your automation solution—from concept to completion—will help you deliver the outcomes you demand.

You’ve decided to automate your lab, but what’s the next step? How do you find the right partner to meet your growth and productivity needs?

With nearly two decades of automation experience, Siemens Healthineers will work closely with your team to define and help you achieve your goals. Utilizing our Lean analysis tools and proprietary simulation models, our healthcare consultants help establish new processes, redefine workflow, and improve staff utilization. And our project management team partners with you to make sure your implementation is a success.

As your long-term partner, Siemens Healthineers will be there—from design and implementation to ongoing optimization of your laboratory’s performance. That’s why so many customers have trusted us for their first and replacement automation solutions. You can always expect our commitment to a seamless transition to your new solution, giving you confidence and peace of mind. And that’s the best news of all.

Get more good news at siemens.com/automation-leader.